Venture Partner, Newpath Partners

Philip DeSouza, MD is a Venture Partner at Newpath Partners, where he leads scientific and technical due diligence for all new investments. As the only fully trained, licensed, and board-certified physician (a vitreoretinal surgeon) on Newpath’s team, Dr. DeSouza brings a unique clinical perspective to the firm’s investment strategy. He has taken on hands-on operating roles in Newpath’s portfolio, including serving as acting CEO, President, and Chief Medical Officer for companies, in addition to his investing activities. Dr. DeSouza has a strong research background, having authored both scientific publications and patents that served as the foundation for Newpath portfolio companies. He currently serves as a director on the boards of Autobahn Therapeutics and Leal Therapeutics, and as an observer for several other companies. He earned his M.D. from Duke University, completed his residency in ophthalmology at Wake Forest University, and his fellowship in vitreoretinal surgery at the University of California, Davis.